Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
yuanhuacine
- Development stage
- Preclinical
- Lead developer
- Ewha Womans University
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Intraperitoneal
01
Overview
Yuanhuacine (also known as yuanhuacin or gnidilatidin) is a daphnane-type diterpene ortho-ester isolated from the flower buds of *Daphne genkwa* (Genkwa Flos). It is a potent natural product being investigated for its anti-inflammatory and anticancer properties. Yuanhuacine acts as a protein kinase C beta (PKCβ) agonist, which mediates its selective cytotoxicity against the basal-like 2 (BL2) subtype of triple-negative breast cancer (TNBC) and promotes an antitumor immune signature. Additionally, it has been shown to inhibit DNA topoisomerase 1, activate the AMPK/mTOR pathway, and promote ASCT2 degradation, leading to growth inhibition in various cancer models, including non-small cell lung cancer (NSCLC), colorectal cancer, and head and neck squamous cell carcinoma (HNSCC).
- Other names
- gnidilatidinodoracinyuanhuacin
02
Targets
AKT (RAC-alpha serine/threonine-protein kinase)TOP1 (DNA Topoisomerase I)F-actin (Filamentous actin)PKC (Protein kinase C family)RAC1 (Rac family small GTPase 1)SP1 (Transcription factor Sp1)CDKN1A (Cyclin-dependent kinase inhibitor 1A)MAPK14 (p38 mitogen-activated protein kinase alpha)PRKCB (Protein kinase C beta)
Beyond the preview
Go deeper on yuanhuacine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on yuanhuacine.